Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2002
06/13/2002WO2002046413A2 Molecules for disease detection and treatment
06/13/2002WO2002046412A2 Regulation of angiogenesis with zinc finger proteins
06/13/2002WO2002046409A2 Proteins and nucleic acids encoding same
06/13/2002WO2002046408A2 Human proteins, polynucleotides encoding them and methods of using the same
06/13/2002WO2002046402A2 Regulation of human patched-like protein
06/13/2002WO2002046394A1 Novel g protein-coupled receptor protein and dna thereof
06/13/2002WO2002046391A2 Transgenic mice containing nori gene disruptions
06/13/2002WO2002046385A2 Enzymes
06/13/2002WO2002046384A2 Kinases and phosphatases sequences, and use thereof
06/13/2002WO2002046383A2 Protein modification and maintenance molecules
06/13/2002WO2002046382A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/13/2002WO2002046380A2 Protein kinase
06/13/2002WO2002046378A2 Alternative pol k nucleotide and amino acid sequence and methods for using
06/13/2002WO2002046367A2 Antisense modulation of cellular apoptosis susceptibility gene expression
06/13/2002WO2002046364A2 Genes associated with mechanical stress, expression products therefrom, and uses thereof
06/13/2002WO2002046362A2 Gene associated with benign prostatic hyperplasia in humans
06/13/2002WO2002046237A2 Humanized antibodies that recognize beta amyloid peptide
06/13/2002WO2002046231A2 Caml-binding peptides
06/13/2002WO2002046230A2 G-protein coupled receptors
06/13/2002WO2002046229A2 Novel proteins and nucleic acids encoding same
06/13/2002WO2002046228A2 Receptor for b. anthracis toxin
06/13/2002WO2002046227A2 Glp-1 fusion proteins
06/13/2002WO2002046226A2 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
06/13/2002WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma
06/13/2002WO2002046221A2 Human protein differentially expressed in alzheimer's disease's brain
06/13/2002WO2002046220A2 Sequences upstream of the carp gene, vectors containing them and uses thereof
06/13/2002WO2002046219A2 Rho-gtpase activating proteins and methods related thereto
06/13/2002WO2002046218A2 Treatment of disease by inducing cell apoptosis
06/13/2002WO2002046217A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/13/2002WO2002046215A2 Basb221 polypeptides and polynucleotides encoding basb221 polypeptides
06/13/2002WO2002046214A2 Immunomodulatory protein derived from the yaba monkey tumor virus
06/13/2002WO2002046213A2 Methods and reagents for isolating angiogenic modulators
06/13/2002WO2002046212A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/13/2002WO2002046211A2 Peptides derived from colostrinin
06/13/2002WO2002046210A1 Method for preparing tryptophan rich peptides
06/13/2002WO2002046206A1 Antisense modulation of damage-specific dna binding protein 1, p127 expression
06/13/2002WO2002045773A2 Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols
06/13/2002WO2002045755A2 Expression of keratin genes 8 and 18 for treating tumours, in particular a mammary carcinoma
06/13/2002WO2002045754A2 Pharmaceutical compositions for the oral delivery of pharmacologically active agents
06/13/2002WO2002045747A1 Immunotherapeutic combinations for the treatment of tumors
06/13/2002WO2002045738A2 Vaccine composition containing transforming growth factor alpha
06/13/2002WO2002045737A2 Methods of treatment involving human mda-7
06/13/2002WO2002045735A2 Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
06/13/2002WO2002045729A1 Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant argania spinosa
06/13/2002WO2002045720A1 Treatment of cancer by reduction of intracellular energy and pyrimidines
06/13/2002WO2002045718A1 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
06/13/2002WO2002045708A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes
06/13/2002WO2002045690A1 Synthesis of small particles
06/13/2002WO2002045682A1 Particulate inhalation carrier
06/13/2002WO2002045659A2 Novel therapeutics for heart failure and aging
06/13/2002WO2002045498A2 Transgenic mice containing channel protein target gene disruptions
06/13/2002WO2002045496A2 Transenic mice containing frp-rs4 gene disruptions
06/13/2002WO2002045494A2 Transgenic mice containing glucagon receptor gene disruptions
06/13/2002WO2002045493A2 Transgenic mice containing phosphatase target gene disruptions
06/13/2002WO2002045492A2 Transgenic mice containing polycystin-related gene disruptions
06/13/2002WO2002028419A3 Chemokine mutants in the treatment of multiple sclerosis
06/13/2002WO2002024213A3 Improved protocol for paracentesis
06/13/2002WO2002022848A3 Compositions comprising mixtures of human cytokines and methods of producing the same
06/13/2002WO2002022663A3 Stress resistant retroviruses
06/13/2002WO2002022156A3 Topical formulations for delivery of interleukin-11
06/13/2002WO2002017948A3 Control of crop pests and animal parasites through direct neuronal uptake
06/13/2002WO2002017856A3 Compositions and methods relating to hypertension
06/13/2002WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage
06/13/2002WO2002012339A3 Sequences for integrin alpha-8
06/13/2002WO2002011751A3 Combinations of dalfopristine/quinupristine with cefpirome
06/13/2002WO2002010404A3 Regulation of human masp-like serine protease
06/13/2002WO2002008418A3 Method of isolation of regulated virulence determinants from bacterial pathogens
06/13/2002WO2002007646A3 Artificial vascular grafts, and methods of producing and using same
06/13/2002WO2002000704A3 Regulation of human phospholipase c-like enzyme
06/13/2002WO2002000701A3 Regulation of human gonadotropin releasing hormone receptor-like g protein-coupled receptor
06/13/2002WO2002000173A3 Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
06/13/2002WO2001098350A3 Compositions comprising net-4 modulations and their use for treating neoplastic disease
06/13/2002WO2001096879A3 Method and apparatus for monitoring anti-platelet agents
06/13/2002WO2001094547A3 Molecular delivery vehicle for delivery of selected compounds to targets
06/13/2002WO2001094415A3 Nuclear hormone receptor
06/13/2002WO2001092294A3 Therapeutic anti-melanoma compounds
06/13/2002WO2001091781A3 Thrombospondin type 1 repeat polypeptides
06/13/2002WO2001090159A3 Compositions and methods for delivery of a molecule into a cell
06/13/2002WO2001089554A3 Treatment of acute coronary syndrome with glp-1
06/13/2002WO2001087981A3 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
06/13/2002WO2001083523A3 Stmst protein and nucleic acid molecules and uses therefor
06/13/2002WO2001077168A3 Compositions and methods for the therapy and diagnosis of lung cancer
06/13/2002WO2001075015A3 A novel polypeptide, fat24 and the polynucleotide encoding the polypeptide
06/13/2002WO2001074844A3 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
06/13/2002WO2001068828A3 Compositions and methods for regulated protein expression in gut
06/13/2002WO2001064889A3 Tnf-alpha variants for the treatment of tnf-alpha related disorders
06/13/2002WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
06/13/2002WO2001042461A3 Apoptin-associating protein
06/13/2002WO2001042291A3 Polynucleotides and polypeptides encoded thereby
06/13/2002WO2001038343A3 Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
06/13/2002WO2000077262A9 Synthetic ligation reassembly in directed evolution
06/13/2002WO2000066741A3 Conserved neisserial antigens
06/13/2002WO2000064957A9 Differentially acting op detoxifying sponges
06/13/2002WO2000064400A9 Methods for treating congestive heart failure
06/13/2002WO2000037022A3 Combination therapy for the treatment of sepsis
06/13/2002US20020073439 Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease
06/13/2002US20020073438 Methods of purifying human acid alpha-glucosidase
06/13/2002US20020072596 Nucleotide sequences coding transrerrins; for use in the treatment of nervous system., blood abbd anemia, heme biosynthesis disorders
06/13/2002US20020072592 Nucleotide sequences which code anticarcinogenic agent for use in the treatment mammary gland cancer
06/13/2002US20020072588 Recombinant antibody fragments as autoantibody antagonists
1 ... 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 ... 3163